The official journal of the Brazilian Diabetes Society.
Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal
Obesity and overweight are a significant public health concern. Subcutaneous semaglutide 2.4 mg injection is a glucagon-like peptide-1 (GLP-1) analogue approved by the European Medicines Agency as an adjunct t...